RxDoctor Payments Data

Matthew Hulst, OD

Optometrist · East China, MINPI 1104304328

Payments from drug & device makers

$4,978in general payments, 2019–2025

Across 85 payments — averaging $58.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
  • Alcon$1K
  • Biotissue Holdings Inc.$661
  • Regeneron Healthcare Solutions, Inc.$360
  • Sun Pharmaceutical Industries Inc.$259
  • AbbVie$184
  • plus $620 from 12 others

What the payments were for

  • Travel & lodging$2,36848%
  • Food & beverage$2,61052%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,978 in reported general payments places this provider in the 95th percentile of 1,523 optometrist providers in Michigan.

See all optometrist providers in Michigan

Medicare billing

Part B allowed, 2024
$139,694
Medicare patients
643
Services billed
1,732

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine47$58,899
LumiganBimatoprost57$27,519
CequaCyclosporine13$14,481
Cyclosporine15$13,601
RocklatanNetarsudil Mesylat/Latanoprost22$7,221
Latanoprost234$4,587
Timolol Maleate80$3,351
Prednisolone Acetate70$2,507
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$1,600
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat31$729
Tobramycin-DexamethasoneTobramycin/Dexamethasone16$602
Brimonidine Tartrate22$381
Doxycycline Hyclate30$293
Dorzolamide Hcl16$179
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha12$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$184$86,418104 claims
Sun Pharmaceutical Industries Inc.Cequa$259$14,48113 claims
Aerie Pharmaceuticals, Inc.Rocklatan$15$7,22122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,523 optometrist providers in Michigan.

Other optometrist in East China

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →